Inventor · disambiguated record
Yannick Aime Eddy Ligny
Also filed as: LIGNY YANNICK · LIGNY YANNICK AIM EACUTE EDDY · LIGNY YANNICK AIME EDDY · Ligny Yannick Aimé Eddy
13 granted patents·4 pending applications·182 citations·filing 1998–2022
89Inventor score
Files withJANSSEN PHARMACEUTICA NV13SAXTY GORDON2ASTEX THERAPEUTICS LTD1LACRAMPE JEAN FERAND ARMAND1
Top patents by PatentIndex Score
17 records- 0197US6187786B1Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazolesJANSSEN PHARMACEUTICA NV·Filed 1998·Granted Feb 13, 2001·119 cites·11 claims
- 0293US9856236B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2015·Granted Jan 2, 2018·16 cites·20 claims
- 0393US9290478B2Substituted quinoxalines as FGFR kinase inhibitorsSAXTY GORDON·Filed 2011·Granted Mar 22, 2016·25 cites·20 claims
- 0484US7834016B2Inhibitors of the interaction between MDM2 and p53JANSSEN PHARMACEUTICA NV·Filed 2005·Granted Nov 16, 2010·8 cites·36 claims
- 0578US7947695B25-membered annelated heterocyclic pyrimidines as kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted May 24, 2011·4 cites·19 claims
- 0675US8404683B2Inhibitors of the interaction between MDM2 and P53LACRAMPE JEAN FERAND ARMAND·Filed 2010·Granted Mar 26, 2013·6 cites·2 claims
- 0773US7947694B2Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted May 24, 2011·2 cites·16 claims
- 0864US6444812B1Intermediate compounds in the preparation of farnnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N-or C linked imidazolesJANSSEN PHARMACEUTICA NV·Filed 2000·Granted Sep 3, 2002·2 cites·2 claims
- 0959US11186589B2Cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 30, 2021·0 cites·20 claims
- 1055US2024101554A1Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 1154US2024254138A1Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2022·Application pending·0 cites
- 1253US2019119299A1Cyanoindoline derivatives as nik inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 1352US2024109912A1Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2021·Application pending·0 cites
- 1439US11136311B2Heteroaromatic derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Oct 5, 2021·0 cites·15 claims
- 1539US9688662B2N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Jun 27, 2017·0 cites·11 claims
- 1635US8722687B2Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapySAXTY GORDON·Filed 2010·Granted May 13, 2014·0 cites·20 claims
- 1730US6498158B1Il-5 inhibiting 6-azauracil derivativesJANSSEN PHARMACEUTICA NV·Filed 1999·Granted Dec 24, 2002·0 cites·7 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →